查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1878093

全球肺炎鏈球菌疫苗市場－2025年至2030年預測

Global Pneumococcal Vaccine Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 114 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球肺炎鏈球菌疫苗市場預計將從 2025 年的 100.58 億美元成長到 2030 年的 136.07 億美元，複合年成長率為 6.23%。

肺炎鏈球菌疫苗旨在預防由肺炎鏈球菌（肺炎鏈球菌）引起的疾病。雖然肺炎鏈球菌感染在幼兒中更為常見，但成人和老年人感染後嚴重感染甚至死亡的風險更高。接種疫苗被廣泛認為是預防這些疾病傳播的重要公共衛生措施，支持了肺炎疫苗的穩定需求。市場擴張得益於幾個關鍵因素，包括基於國家政策實施的常規免疫規劃、公眾對肺炎認知的提高，以及世界衛生組織（WHO）和聯合國兒童基金會（UNICEF）等國際組織的策略指南（通常輔以政府的大力支持）。

主要市場成長促進因素

全球肺炎鏈球菌疫苗市場的主要促進因素是兒童肺炎的高發生率。在所有影響兒童的感染疾病中，肺炎是全球兒童死亡的首要原因。高死亡率，尤其是在五歲以下嬰幼兒中，使得遏制兒童死亡成為一項緊迫的公共衛生挑戰。這種嚴峻形勢推動了對有效預防措施的需求，從而刺激了肺炎球菌疫苗市場的成長。南亞、西非和中非等某些地區的肺炎發生率尤其高，進一步凸顯了廣泛進行疫苗接種活動的必要性。

同時，疾病防治宣傳活動的擴大和政府政策的支持也為市場帶來了新的成長機會。肺炎鏈球菌疫苗主要用於預防兒童肺炎，國際組織正與各國政府合作，降低感染率，尤其是在弱勢族群。國家疫苗接種計劃的實施，例如在全民免疫舉措下擴大肺炎球菌結合疫苗（PCV）的接種範圍，旨在提高公眾意識並增強兒童的免疫系統。這些計劃和政策透過鼓勵新產品的推出和現有產品組合的擴展，刺激了疫苗市場的發展。此外，國際組織對肺炎負擔沉重的開發中國家的支持，透過改善疫苗的可近性，也促進了市場的成長趨勢。

市場區隔分析

全球肺炎鏈球菌疫苗市場依類型分為結合疫苗和多醣體疫苗。預計結合疫苗市場將實現顯著成長。此細分市場的擴張主要得益於疫苗在預防肺炎和腦膜炎等嚴重的有效性，這些疾病主要影響嬰幼兒和老年人。持續不斷的疫苗研發工作不斷提升疫苗的效力，新核准也擴大了對更多肺炎鏈球菌血清型的保護範圍，從而持續推動該細分市場的成長。

本報告按地區分析了北美、南美、歐洲、中東和非洲以及亞太地區的市場。北美預計將佔據顯著的市場佔有率。這一主導地位得益於各方為遏制兒童和成人肺炎傳播所做的共同努力，促使監管機構核准了新型先進疫苗。此外，眾多生技和製藥公司積極參與疫苗研發，進一步鞏固了該地區的市場地位。肺炎鏈球菌疫苗的持續研發，以及疾病的持續蔓延，將繼續推動北美市場的整體成長。

市場限制

全球肺炎鏈球菌疫苗市場面臨的主要阻礙因素是疫苗生產高成本。疫苗研發過程不僅耗資巨大，而且耗時漫長，因為必須經過多個階段的嚴格測試和監測，以確保其安全性和有效性。這種耗時耗資的特性對市場成長構成了重大挑戰。然而，政府對疫苗生產的補貼以及國際組織的資助在一定程度上緩解了這一障礙，這些資金支持了疫苗的研發和分發。

主要市場趨勢

市場特徵是主要企業持續活躍，專注於先進候選疫苗的研發和商業化。近期策略進展包括監管機構對新型疫苗的正面評價，這些疫苗能夠擴大對侵襲性疾病的保護範圍，涵蓋從嬰幼兒到成人的廣泛年齡層。此外，各公司已達成商業生產協議，以加強肺炎鏈球菌結合疫苗候選產品的生產和商業化。這些合作利用了現有的生產基礎設施和專業技術，擴大了供應，滿足了全球需求，體現了充滿活力且面向未來的產業格局。

本報告的主要優勢：

  • 深入分析：提供對主要和新興地區的深入市場洞察，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、行業垂直領域和其他細分市場。
  • 競爭格局：了解全球主要企業的策略舉措，並了解透過正確的策略實現市場滲透的潛力。
  • 市場促進因素與未來趨勢：探討影響市場的動態因素和關鍵趨勢及其對未來市場發展的影響。
  • 可操作的建議：利用這些見解，在快速變化的環境中製定策略決策，發展新的商業機會和收入來源。
  • 受眾廣泛：適用於Start-Ups、研究機構、顧問公司、中小企業和大型企業，且經濟實惠。

企業使用我們的報告的目的是什麼？

產業與市場分析、機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法規結構及影響、新產品開發、競爭情報

報告範圍：

  • 2022年至2024年的歷史數據和2025年至2030年的預測數據
  • 成長機會、挑戰、供應鏈前景、法規結構與趨勢分析
  • 競爭定位、策略和市場佔有率分析
  • 按業務板塊和地區分類的收入成長和預測評估，包括國家/地區
  • 公司概況（策略、產品、財務資訊、關鍵發展等）

全球肺炎鏈球菌疫苗市場已按以下方式進行細分和分析：

  • 肺炎鏈球菌疫苗市場按類型分類
  • 結合疫苗
  • 多醣體疫苗
  • 按應用分類的肺炎鏈球菌疫苗市場
  • 常規疫苗接種
  • 疾病及感染疾病接種
  • 按地區分類的肺炎鏈球菌疫苗市場
  • 北美洲
  • 美國
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 其他
  • 歐洲
  • 德國
  • 法國
  • 英國
  • 西班牙
  • 其他
  • 中東和非洲
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 印尼
  • 泰國
  • 其他

目錄

第1章執行摘要

第2章 市場概覽

  • 市場概覽
  • 市場定義
  • 調查範圍

第2章 4. 市場區隔

第3章 商業情境

  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 波特五力分析
  • 產業價值鏈分析
  • 政策與法規
  • 策略建議

第4章 技術展望

5. 肺炎鏈球菌疫苗市場（按類型分類）

  • 介紹
  • 結合疫苗
  • 多醣體疫苗

6. 按應用分類的肺炎鏈球菌疫苗市場

  • 介紹
  • 常規疫苗接種
  • 疫苗接種預防疾病及感染疾病

7. 各地區肺炎鏈球菌疫苗市場

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 其他
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 印尼
    • 泰國
    • 其他

第8章 競爭格局與分析

  • 主要企業和策略分析
  • 市佔率分析
  • 合併、收購、協議和合作
  • 競爭對手儀錶板

第9章：公司簡介

  • Pfizer
  • GSK
  • Merck
  • AstraZeneca
  • Serum Institute of India Pvt Ltd
  • Sanofi
  • CSL Limited
  • Walvax Biotechnology Co. Ltd

第10章附錄

  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要收益
  • 調查方法
  • 簡稱
簡介目錄
Product Code: KSI061611187

The global pneumococcal vaccine market is forecasted to rise at a 6.23% CAGR, reaching USD 13.607 billion by 2030 from USD 10.058 billion in 2025.

Pneumococcal vaccines are designed to prevent disease caused by the bacterium Streptococcus pneumoniae. While pneumococcal diseases are common in young children, adults and the elderly demonstrate a higher susceptibility to severe contamination and mortality. Immunization is widely recognized as a critical public health measure to prevent the spread of such diseases, thereby driving consistent demand for pneumonia vaccines. The market's expansion is supported by several key factors, including the implementation of regular vaccination programs under national policies, rising public awareness against pneumonia, and strategic directives launched by international bodies like the World Health Organization (WHO) and UNICEF, often backed by increasing government support.

Primary Market Growth Drivers

A significant driver for the global pneumococcal vaccine market is the substantial incidence of childhood pneumonia. Among all infectious diseases affecting children, pneumonia is a leading cause of mortality globally. The high number of fatalities, particularly among children under the age of five, creates an urgent public health imperative to combat child mortality rates. This alarming situation is expanding the demand for effective prophylactic measures, thereby stimulating market growth for pneumococcal vaccines. The incidence rates are notably higher in certain regions, such as South Asia and West and Central Africa, which further underscores the need for widespread vaccination efforts.

Concurrently, growing disease awareness campaigns and supportive government policies are providing new growth prospects. Pneumococcal vaccines are primarily administered to children to protect them from illness, prompting international organizations to collaborate with national governments to reduce infection rates, especially among vulnerable populations. The implementation of nationwide vaccine programs, such as the expansion of pneumococcal conjugate vaccine (PCV) under universal immunization initiatives, aims to spread awareness and boost children's immune systems. These plans and policies invigorate the vaccine market by facilitating the introduction of novel products and the expansion of existing portfolios. Furthermore, aid from international organizations to underdeveloped countries with high pneumonia prevalence rates is contributing to an upward market trajectory by increasing vaccine accessibility.

Market Segment Analysis

The global pneumococcal vaccine market is segmented by type into conjugate vaccines and polysaccharide vaccines. The conjugate vaccine segment is anticipated to demonstrate remarkable growth. This segment's expansion is fueled by the vaccine's efficacy in providing immunity against serious diseases such as pneumonia and meningitis, which predominantly affect infants and older adults. Ongoing research and development efforts to enhance these vaccines continue to provide a major boost to the segment's growth, with new approvals expanding their protective coverage against a broader range of pneumococcal serotypes.

Geographically, the market is analyzed across North America, South America, Europe, the Middle East and Africa, and the Asia Pacific. North America is estimated to constitute a remarkable market share. This dominance is fueled by concerted efforts to reduce the spread of pneumonia among children and adults, leading regulatory authorities to grant approvals for new and advanced vaccines. The presence of major biotech and pharmaceutical manufacturers actively engaged in vaccine development further solidifies the region's market position. The ongoing development of pneumococcal vaccines, coupled with the persistent prevalence of the disease, continues to drive overall market growth in North America.

Market Restraints

A primary restraint on the global pneumococcal vaccine market is the high cost associated with vaccine production. The process of developing a vaccine is not only expensive but also involves a long duration, requiring passage through various phases of rigorous testing and monitoring to ensure safety and efficacy. This time-consuming and capital-intensive nature presents a significant challenge to market growth. However, this hurdle is partially mitigated by government subsidies for vaccine production and funds released by international organizations, which help to support the development and distribution pipeline.

Key Market Developments

The market is characterized by continuous activity from key players, focusing on the development and commercialization of advanced vaccine candidates. Recent strategic developments include positive regulatory opinions for new vaccines that offer broader protection against invasive diseases across various age groups, from infants to adults. Furthermore, companies are entering into commercial manufacturing agreements to bolster the production and commercialization of their pneumococcal conjugate vaccine candidates. Such collaborations leverage established manufacturing infrastructure and expertise to ensure scalable supply and meet global demand, reflecting a dynamic and forward-looking industry landscape.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

The Global Pneumococcal Vaccine market is segmented and analyzed as follows:

  • PNEUMOCOCCAL VACCINES MARKET BY TYPE
  • Conjugate Vaccines
  • Polysaccharide Vaccines
  • PNEUMOCOCCAL VACCINES MARKET BY APPLICATION
  • Routine Vaccination
  • Vaccination For Disease/Infection
  • PNEUMOCOCCAL VACCINES MARKET BY GEOGRAPHY
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. PNEUMOCOCCAL VACCINES MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Conjugate Vaccines
  • 5.3. Polysaccharide Vaccines

6. PNEUMOCOCCAL VACCINES MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Routine Vaccination
  • 6.3. Vaccination For Disease/Infection

7. PNEUMOCOCCAL VACCINES MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. USA
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others
  • 7.4. Europe
    • 7.4.1. Germany
    • 7.4.2. France
    • 7.4.3. United Kingdom
    • 7.4.4. Spain
    • 7.4.5. Others
  • 7.5. Middle East and Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. UAE
    • 7.5.3. Others
  • 7.6. Asia Pacific
    • 7.6.1. China
    • 7.6.2. India
    • 7.6.3. Japan
    • 7.6.4. South Korea
    • 7.6.5. Indonesia
    • 7.6.6. Thailand
    • 7.6.7. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. Pfizer
  • 9.2. GSK
  • 9.3. Merck
  • 9.4. AstraZeneca
  • 9.5. Serum Institute of India Pvt Ltd
  • 9.6. Sanofi
  • 9.7. CSL Limited
  • 9.8. Walvax Biotechnology Co. Ltd

10. APPENDIX

  • 10.1. Currency
  • 10.2. Assumptions
  • 10.3. Base and Forecast Years Timeline
  • 10.4. Key Benefits for the Stakeholders
  • 10.5. Research Methodology
  • 10.6. Abbreviations